I'm sure Dr.Tefferi has a handle on customizing patient protocol where deemed necessary. If his main concern is patient's welfare why wouldn't he allow a greater period between infusion if the previous was deemed unnecessary? Just as a reduction in dosing if negative side effects were noticed earlier. This an experimental trial study and Dr.Tefferi is charged with the patient's health as his #1 priority and tweaking protocol as needed for each patient. You're showing you lack of understanding on such matters.
Rochester Minnesota isn't exactly in everyone's backyard. Many participating in the trial went to the Mayo as a privately sponsored facility to access cutting edge experimental treatment not available to the public. You have no clue as to the trial protocol MAYO has in place unless you've gone through it yourself. Last time I attended, it was not cheap. Why do you continually have to change your handle? No credibility?
She's expressed her concerns and frustrations with public forums like MPN where most current 'expert' opinion is stacked in favour of dumbing down desperate MF cancer patients into accepting short term symptomatic relief from drugs like ruxolitinib, which btw was effective in mice and in three people with Alopecia but with what side effects? It masks the cancer's disease progression without offering any potential remission or clinical cure.
Late-breaking abstract submission site now open. The deadline for late-breaking abstract submission is October 28, 2014, 11:59 p.m. PDT
heading submission....this just in from Geron;
The Surprising Link Between Porsche Racing and Running A Successful Biotech Company
Who knew that running a successful biotech company often relies upon similar best practices found in auto racing success? Join Dr. John "Chip" Scarlett, CEO and President of Geron Corporation of Menlo Park, for an interesting discussion about how leaders can use auto racing principles to guide successful biotech ventures.
Oh and maybe mention about IMET's MF cures
SP should open @ $5 tomorrow.
Late Breaking Abstract Submission Website Open
The selection process for late-breaking abstracts is extremely competitive; a maximum of six abstracts will be selected, regardless of the number of submissions. This deadline is not intended as an extension of the general submission deadline. Abstract reviewers will focus on capturing abstracts with groundbreaking, novel data that otherwise could not be presented at the annual meeting.
So far no indication GERON has even made a submission. What was all the ASH embargo talk about if there's no submission?
rx my earlier reply was censored but I feel I must repost. You're as delicate as a flatulence filled bear blowing bubbles and creating ripples as you try to wade across through the water lilies on the tranquil waters of beaver pond.
Geron missed some follow up blood work and was slapped with a clinical hold meanwhile you're claiming monthly sampling isn't std. on blood cancer...give me a willow stick break.
scarier than a halloween mask, ruxolitinib masks the cancer's progress while briefly treating some symptoms. And yet the FDA delay's IMET's development? Jason's behind the INCY mask!
from the Issue of British Journal of Haematology
British Journal of Haematology
Volume 167, Issue 1, pages 144–146, October 2014
"There is no evidence that ruxolitinib increases the rate of transformation to AML, but our data does suggest that it does not delay clonal evolution, even while masking disease-related symptoms. Whether ruxolitinib alters the trafficking of MF leukaemia cells by affecting chemokine or integrin expression, or cytokine or chemokine levels will require further investigation. These observations clearly lead one to question the wisdom of delaying allo-SCT in MF patients receiving ruxolitinib even though they are symptomatically improved."
.....what just happened to rhortons944 post on "Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis" ?
In simple terms ruxolitinib does not delay clonal evolution of cancer, even while masking disease-related symptoms meaning it's actually masking the cancer's progression and lessens detection of the cancer's advancement. This IS alarming considering the FDA is behind such a drug
Most damming evidence against the use of ruxolitinib to date.
in simple terms ruxolitinib does not delay clonal evolution of cancer, even while masking disease-related symptoms meaning it's actually masking the cancer's progression and lessens detection of the cancer's advancement. This IS alarming considering the FDA is behind such a drug.
...to date Irish has reported her husband John has had a functional cure in that his cancer has been in remission over 17 months now with disease modifying effects; Irishtrader52 posted Tues. Sep 2, 2014 7:26 PM "Imetelstat cleared fibrosis in marrow and that is disease modification and best measure of disease progression or not. More predictive than any blood chemistry as endpoint. Essentially a chemical bone marrow transplant as I see it. Exceeding life expectancy (LE) in IST MF trial is very close to meeting that new endpoint for Phase III). John is 17 months on Imetelstat and doing great. He exceeds his intermediate high risk LE at approximately 24 months. You could argue he already exceeded LE given his date of diagnosis rather than treatment start date as LE baseline. He by no means is alone."
I'll soon be able to afford a Tesla
no more gas pumps
no more carbon footprint
no more dirty environmentalist's looks
Tesla, the I-pod of the auto industry
furthermore the long term descending line of resistance has disappeared as of yesterday meaning the $2.68 200SMA should easily be taken out. How high we go depends on 30 million shorts covering. Here's to strong abstract data support next week forcing their hand.
I year ago pre ASH we were @ $3.66